Literature DB >> 810403

Studies of the genetic susceptibility of individuals to infection with influenza viruses.

I J Watkin, D Tills, R B Heath.   

Abstract

Nearly three and a half thousand sera obtained from various populations were tested serologically to obtain evidence of past infection with influenza A viruses that were prevalent from 1947 to 1972. No significant difference was found between the distributions of the levels of these antibodies of individuals of blood groups A and O, A1 and O, Rh (D+) and Rh (D-) and MM, MN and NN. The significance of these findings is discussed.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 810403     DOI: 10.1007/BF00273634

Source DB:  PubMed          Journal:  Humangenetik        ISSN: 0018-7348


  3 in total

1.  ABO Blood Groups and Acute Respiratory Virus Disease.

Authors:  J C McDonald; A J Zuckerman
Journal:  Br Med J       Date:  1962-07-14

2.  Antibodies of influenza viruses in military recruits from Argentina, Brazil and Colombia. Their relation to ABO blood group distribution.

Authors:  R R Cuadrado; F M Davenport
Journal:  Bull World Health Organ       Date:  1970       Impact factor: 9.408

3.  The incidence of HI antibody to Influenza virus A2/Singapore/ 1/57 in individuals of blood groups A and O.

Authors:  C W Potter; G C Schild
Journal:  J Immunol       Date:  1967-06       Impact factor: 5.422

  3 in total
  3 in total

Review 1.  Relationship between infectious diseases and human blood type.

Authors:  S A Berger; N A Young; S C Edberg
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-08       Impact factor: 3.267

Review 2.  Influenza Pathogenesis: The Effect of Host Factors on Severity of Disease.

Authors:  Anshu P Gounder; Adrianus C M Boon
Journal:  J Immunol       Date:  2019-01-15       Impact factor: 5.422

Review 3.  The role of host genetics in susceptibility to influenza: a systematic review.

Authors:  Peter Horby; Nhu Y Nguyen; Sarah J Dunstan; J Kenneth Baillie
Journal:  PLoS One       Date:  2012-03-15       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.